Andere Sprachen Everest Medicines Limited

Aktien

A2QD66

KYG3224E1061

1952

Verzögert Hong Kong S.E. Andere Börsenplätze 10:08:06 30.04.2024			% 5 Tage	% 1. Jan.
24,45 ^HKD	+2,52 %		+4,71 %	+16,99 %

25.04.	Everest Medicines' Verlust weitet sich 2023 aus	MT
28.03.	Everest Medicines Limited meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Everest Medicines' Loss Widens in 2023	25.04.
Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023	28.03.
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer	18.03.
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer	18.03.
Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024	06.03.
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis	27.02.
Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis	22.02.
Everest Medicines Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam's Phase 3 CERTAIN-1 Study in New England Journal of Medicine	21.02.
Calliditas Year-end report, January - December 2023	21.02.
Everest Medicines Announces Termination of Collaboration Agreements with Providence	19.02.
Everest Medicines Terminates Collaboration with Canada’s Providence for mRNA COVID-19 Vaccines	19.02.
Everest Medicines Limited Announces Board Changes	09.02.
Everest Medicines Announces 2023 Revenue Expected to be Between RMB124 Million and RMB126 Million	22.01.
Everest Foresees Surge in 2023 Revenue	22.01.
Everest Medicines Limited Provides Earning Guidance for the Year Ended 31 December 2023	21.01.
Everest Medicines Limited Announces Directorate Changes	12.01.
Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients	27.12.
Everest Medicines Partner Calliditas Therapeutics Announces Nefecon the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline	22.12.
Everest Medicines' Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline	21.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Everest Medicines Limited

Aktien

A2QD66

KYG3224E1061

1952

Andere Sprachen

Filter